Triple Hormonal Blockade (ADT3): A Patient’s Perspective

    January 2019 in “ Oncogen ”
    Charles Maack
    Image of study
    TLDR Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
    The document discussed the use of Triple Hormonal Blockade (ADT3) in managing prostate cancer, which involved a combination of a GnRH agonist or antagonist, an antiandrogen, and a 5Alpha Reductase inhibitor to effectively reduce testosterone and dihydrotestosterone (DHT) levels, thereby inhibiting cancer cell growth. It highlighted the importance of these medications in various treatment stages and emphasized the need for physicians to conduct necessary tests to rule out cardiac risks, especially in patients with pre-existing cardiovascular conditions, diabetes, or those over 70. The document also referenced a report suggesting that using the GnRH antagonist degarelix could potentially reduce cardiac events in patients with cardiovascular disease compared to GnRH agonists.
    Discuss this study in the Community →

    Related Community Posts Join

    5 / 5 results

    Similar Research

    5 / 768 results
      Targets to Treat Androgen Excess in Polycystic Ovary Syndrome

      research Targets to Treat Androgen Excess in Polycystic Ovary Syndrome

      14 citations, September 2015 in “Expert Opinion on Therapeutic Targets”
      The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.

      research Diseases Of The Canine Prostate Gland

      1 citations, August 2022 in “Veterinary medicine and science”
      The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.
      Understanding and Addressing Hair Disorders in Transgender Individuals

      research Understanding and Addressing Hair Disorders in Transgender Individuals

      32 citations, January 2018 in “American Journal of Clinical Dermatology”
      Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.
      Endocrinology of Transgender Medicine

      research Endocrinology of Transgender Medicine

      166 citations, October 2018 in “Endocrine Reviews”
      Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.